RESEARCH ARTICLE
HIV and HAART-Associated Dyslipidemia
Eoin R Feeney1, *, Patrick W.G Mallon 1, 2
Article Information
Identifiers and Pagination:
Year: 2011Volume: 5
First Page: 49
Last Page: 63
Publisher ID: TOCMJ-5-49
DOI: 10.2174/1874192401105010049
Article History:
Received Date: 15/12/2010Revision Received Date: 01/01/2011
Acceptance Date: 06/01/2011
Electronic publication date: 24/02/2011
Collection year: 2011
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection has led to marked improvement in life-expectancy for those infected with HIV. Despite reductions in the incidence of AIDS with effective treatment, patients continue to experience considerable morbidity and mortality from non-AIDS illness such as premature cardiovascular disease, liver failure and renal failure. These morbidities, particularly premature cardiovascular disease, are thought to be related to a combination of the effects of an ageing HIV-infected population coupled with long-term effects of HIV infection and antiretroviral therapy (ART). One of the principle drivers behind the well documented increase in the risk of cardiovascular disease in HIV-infected patients is dyslipidemia.
This review will focus on the clinical presentation of HIV and ART-associated dyslipidemia, what is known of its patho-physiology, including associations with use of specific antiretroviral medications, and suggest screening and management strategies.
